Abstract
Hemophilia A is an inherited bleeding disorder caused by a deficiency of factor VIII coagulant activity (FVIII:C). Patients are treated with infusions of either plasma-derived or recombinant factor VIII. However, some patients develop inhibitory antibodies (inhibitors) to infused factor VIII which render it ineffective. The original Bethesda method was developed to standardize measurement of inhibitors in a factor VIII neutralization assay. One Bethesda unit is defined as that amount of inhibitor that results in 50% residual FVIII:C activity of a defined test mixture. In the Nijmegen modification of the original Bethesda method, the pH and the protein concentration of the test mixture is further standardized. As a result, the FVIII:C in the test mixture is less prone to artifactual deterioration and the test has improved specificity. Even with a standardized procedure a number of factors can affect the performance of the test and it is important for laboratory staff to be aware of their impact on the result outcome.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594–598
Scharrer I, Neutzling O (1993) Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagul Fibrinolysis 4:753–758
Wright J, Paisley S (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9:418–435
Hay CRM (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 4:558–563
Oldenburg J, El-Maarri O, Schwaab R (2002) Inhibitor development in correlation to factor VIII genotypes. Haemophilia 8(Suppl 2):23–29
Peerlink K, Hermans C (2006) Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 12:579–590
Hay CRM, Brown S, Collins PW, Keeling DM, Liesner R (2006) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organization. Brit J Haematol 133:591–605
Dimichele DM (2006) Inhibitor treatment in haemophilias A and B: inhibitor diagnosis. Haemophilia 12(Suppl 6):37–42
Kasper CK, Aledort LM, Counts RB, Edson JR, Frantantoni J, Green D et al (1975) A more uniform measurement of factor VIII inhibitors. Thrombos Diath Haemorrh 34:869–872
Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 73:247–251
Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I, and the Association of Haemophilia Centre Directors of Canada (1998) A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population in Canada. Thromb Haemost 79:872–875
Gadarowski JJ, Czapek EE, Ontiveros JD, Pedraza JL (1988) Modification of the Bethesda assay for factor VIII and IX inhibitors to improve efficiency. Acta Haematol 80:134–138
Hay CRM, Baglin TP, Collins PW, Hill FGH, Keeling DM (2000) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Brit J Haematol 111:78–90
Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O et al (2003) Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 101:4783–4788
Favaloro EJ, Posen J, Ramakrishna R, Soltani S, McRae S, Just S et al (2004) Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 15:637–647
Gatti L, Mannucci PM (1984) Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost 51:379–384
Ling M, Duncan EM, Rodgers SE, Street AM, Lloyd JV (2003) Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with haemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 1:2548–2553
Verbruggen B, Novakova I, van Heerde W (2009) Detecting and quantifying functional inhibitors in haemostasis. In: Kitchen S, Olson JD, Preston FE (eds) Quality in laboratory haemostasis and thrombosis, 1st edn. Blackwell Publishing, Oxford, Chapter 20
Kasper CK (1995) Laboratory diagnosis of factor VIII inhibitors. In: Kessler C, Garvey MB, Green D, Kasper C, Lusher J (eds) Acquired haemophilia, 2nd edn. Excerpta Medica, Princeton, NJ, Chapter 2
Goldsmith J (1993) Diagnosis of factor VIII versus nonspecific inhibitors. Semin Haematol 30(Suppl 1):3–6
Ling M, Duncan EM, Rodgers SE, Somogyi AA, Crabb GA, Street AM, Lloyd JV (2001) Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. Brit J Haematol 114:861–867
Sahud MA (2000) Laboratory diagnosis of inhibitors. Semin Thromb Hemostas 26:195–203
Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novakova I (2001) The type of factor deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors. Thromb Haemost 86:1435–1439
Verbruggen B, van Heerde W, Novakova I, Lillicrap D, Giles A (2002) A 4% solution of bovine serum albumin may be used in the place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 88:362–364
Reber G, Aurousseau MH, Dreyfus M, Delahousse B, Caron C, Trzeciack MC et al (1999) Inter-laboratory variability of the measurement of low titer factor VIII:C inhibitor in haemophiliacs: improvement by the Nijmegen modification of the Bethesda assay and the use of common lyophilized plasmas. Haemophilia 5:292–293
Favaloro EJ, Bonar R, Duncan E, Earl G, Low J, Aboud M et al (2006) Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 96:73–78
Ewing NP, Kasper CK (1982) In Vitro detection of mild inhibitors to factor VIII in hemophilia. Am J Clin Pathol 77:749–752
Keeling D, Beavis J, Sukhu K (2005) A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B. Brit J Haematol 128:885
Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P et al (1996) High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Brit J Haematol 93:688–693
White GC (1994) Factor VIII inhibitor assay: quantitative and qualitative assay limitations and development needs. Semin Haematol 31(Suppl 4):6–10
Blanco AN, Peirano AA, Grosso SH, Gennari LC, Bianco RP, Lazzari MA (2002) A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant. Haematologica 87:271–278
Manco-Johnson MJ, Nuss R, Jacobson LJ (2000) Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med 136:74–79
Keeney M, Allan DS, Lohmann RC, Chin Yee IH (2005) Effect of recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX. Lab Haematol 11:118–123
Barrow RT, Lollar P (2006) Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost 4:2223–2229
Lloyd JV, Duncan EM, Street AM, Maxwell EL, Berry E, Rowell J et al (1997) Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand. Aust N Z J Med 27:658–664
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this protocol
Cite this protocol
Duncan, E., Collecutt, M., Street, A. (2013). Nijmegen-Bethesda Assay to Measure Factor VIII Inhibitors. In: Monagle, P. (eds) Haemostasis. Methods in Molecular Biology, vol 992. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-339-8_24
Download citation
DOI: https://doi.org/10.1007/978-1-62703-339-8_24
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-338-1
Online ISBN: 978-1-62703-339-8
eBook Packages: Springer Protocols